Immunotherapy for Malignant Pleural Mesothelioma. Current Status and Future Prospects-Reference-Cited by-同舟云学术

Immunotherapy for Malignant Pleural Mesothelioma. Current Status and Future Prospects

Published:2014-05 Issue:5 Volume:50 Page:870-875
ISSN:1044-1549
Container-title:American Journal of Respiratory Cell and Molecular Biology
language:en
Short-container-title:Am J Respir Cell Mol Biol

Author:

Wong Raymond M.,Ianculescu Irina,Sharma Sherven,Gage Diana L.,Olevsky Olga M.,Kotova Svetlana,Kostic Marko N.,Grundfest Warren S.,Hou Dongmei,Cameron Robert B.

Publisher

American Thoracic Society

Subject

Cell Biology,Clinical Biochemistry,Pulmonary and Respiratory Medicine,Molecular Biology

Reference48 articles.

1. Asbestos exposure indices

2. Malignant Pleural Mesothelioma

3. Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

4. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma

5. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Listeria monocytogenes: a promising vector for tumor immunotherapy;Frontiers in Immunology;2023-10-06

2. INVESTIGATION OF PD-L1 (CD274), PD-L2 (PDCD1LG2), AND CTLA-4 EXPRESSIONS IN MALIGNANT PLEURAL MESOTHELIOMA BY IMMUNOHISTOCHEMISTRY AND REAL-TIME POLYMERASE CHAIN REACTION METHODS;POL J PATHOL;2022

3. Carbon Nanotubes under Scrutiny: Their Toxicity and Utility in Mesothelioma Research;Applied Sciences;2020-06-29

4. MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review;Frontiers in Oncology;2018-12-21

5. A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma – the SKOPOS trial;OncoImmunology;2018-09-07